Author, date, study type, level of evidence, Heyland score | Patient group | Complications reported | Nutritional outcomes |
Dann et al. 2015
Retrospective Cohort Study
CEBM Level 4
Heyland Score (/11): 5 | Total = 492
J-tube group = 79 (16.1%)
No J-tube = 413 (83.9%) | Any Complication: 35.4% JT vs. 34.1% No JT
Major Complication^: 11.4% JT vs. 12.8% No JT
Infectious Complication*: 27.8% JT vs. 16.9% No JT
Surgical Site Infection: 12.7% JT vs. 4.6% No JT*
Deep Intra-Abdominal Infection: 7.6% JT vs. 3.1% No JT
Reoperation: 3.8% JT vs. 4.6% No JT
30-Day Readmission: 10.1% JT vs. 11.6% No JT | Length of Stay (days): 12.4 (±8.8) JT vs. 9.6 (±8.7) No JT*
Adjuvant Chemotherapy: 52.0% JT vs. 51.0% No JT
Adjuvant Radiation Therapy: 38.7% JT vs. 32.5% No JT
Any Adjuvant Therapy: 52.0% JT vs. 51.8% No JT |
Patel et al. 2013
Retrospective Cohort Study
CEBM Level 4
Heyland Score (/11): 5 | Total = 86
J-tube: 34 (39.5%)
No J-tube: 52 (60.5%) | Any Complication: 65% JT vs. 40% No JT*
Infectious Complication: 38% JT vs. 17% No JT*
Major Complication^: 15% JT vs. 8% No JT
Reoperation: 3% JT vs. 2% No JT
Bleeding Requiring Packed RBC Transfusion: 3% JT vs. 0% No JT
Anastomotic Leak: 0% JT vs. 2% No JT
30-Day Readmission: 6% JT vs. 15% No JT | Length of Stay (days): 13 (7 - 33)a JT vs. 11 (2 - 52)a No JT
Albumin Pre-Operative: 3.5 (2.2 - 4.4)a JT vs. 3.5 (2.2 - 4.6)a No JT
Albumin 30-Day: 3.3 (1.8 - 4.3)a JT vs. 3.2 (1.2 - 4.4)a No JT
Albumin 60-Day: 3.7 (3.0 - 4.4)a JT vs. 3.5 (2.1 - 4.4)a No JT
Albumin 90-Day: 3.4 (1.4 - 4.3)a JT vs. 3.4 (1.5 - 4.2)a No JT
Received Adjuvant Therapy Post-Op: 56% JT vs. 52% No JT |